First National Bank of Omaha’s Edwards Lifesciences EW Stock Holding History

First National Bank of Omaha’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.08M	Sell	38,519 -337	-0.9%	-$27.8K	0.1%	211
2025 Q4	$3.31M	Sell	38,856 -613	-2%	-$50.3K	0.1%	207
2025 Q3	$3.07M	Sell	39,469 -1,923	-5%	-$150K	0.19%	141
2025 Q2	$3.24M	Buy	41,392 +9,110	+28%	+$679K	0.21%	135
2025 Q1	$2.34M	Sell	32,282 -13,060	-29%	-$935K	0.16%	164
2024 Q4	$3.36M	Sell	45,342 -2,849	-6%	-$199K	0.22%	118
2024 Q3	$3.18M	Sell	48,191 -3,795	-7%	-$276K	0.2%	142
2024 Q2	$4.8M	Buy	51,986 +19,704	+61%	+$1.74M	0.32%	100
2024 Q1	$2.34M	Sell	32,282 -31,489	-49%	-$2.65M	0.16%	164
2023 Q4	$4.86M	Sell	63,771 -9,711	-13%	-$676K	0.31%	109
2023 Q3	$5.09M	Sell	73,482 -9,281	-11%	-$746K	0.33%	101
2023 Q2	$7.81M	Buy	82,763 +27,038	+49%	+$2.35M	0.45%	72
2023 Q1	$4.61M	Sell	55,725 -1,994	-3%	-$157K	0.28%	119
2022 Q4	$4.31M	Sell	57,719 -2,879	-5%	-$222K	0.27%	123
2022 Q3	$5.01M	Sell	60,598 -2,502	-4%	-$241K	0.33%	100
2022 Q2	$6M	Sell	63,100 -2,170	-3%	-$225K	0.36%	90
2022 Q1	$7.68M	Sell	65,270 -2,218	-3%	-$249K	0.39%	80
2021 Q4	$8.74M	Sell	67,488 -2,604	-4%	-$304K	0.42%	70
2021 Q3	$7.93M	Sell	70,092 -17,671	-20%	-$2.02M	0.4%	72
2021 Q2	$7.34M	Hold	87,763	–	–	0.38%	82
2021 Q1	$7.34M	Buy	87,763 +15,938	+22%	+$1.35M	0.38%	82
2020 Q4	$6.55M	Sell	71,825 -28	-0%	-$2.32K	0.36%	88
2020 Q3	$5.74M	Sell	71,853 -852	-1%	-$66.5K	0.36%	90
2020 Q2	$5.02M	Sell	72,705 -165	-0.2%	-$11.7K	0.34%	100
2020 Q1	$4.58M	Sell	72,870 -1,188	-2%	-$85.7K	0.36%	94
2019 Q4	$5.76M	Sell	74,058 -6,183	-8%	-$483K	0.35%	95
2019 Q3	$5.88M	Sell	80,241 -22,032	-22%	-$1.55M	0.38%	89
2019 Q2	$6.3M	Sell	102,273 -9,630	-9%	-$582K	0.41%	77
2019 Q1	$7.14M	Sell	111,903 -336	-0.3%	-$19.2K	0.49%	66
2018 Q4	$5.73M	Sell	112,239 -4,029	-3%	-$204K	0.43%	76
2018 Q3	$6.75M	Sell	116,268 -1,707	-1%	-$83.5K	0.38%	90
2018 Q2	$5.72M	Sell	117,975 -303	-0.3%	-$14.1K	0.34%	100
2018 Q1	$5.5M	Sell	118,278 -17,412	-13%	-$756K	0.33%	99
2017 Q4	$5.1M	Sell	135,690 -6,405	-5%	-$235K	0.3%	107
2017 Q3	$5.18M	Sell	142,095 -5,319	-4%	-$203K	0.32%	104
2017 Q2	$5.81M	Sell	147,414 -44,190	-23%	-$1.61M	0.36%	91
2017 Q1	$6.01M	Sell	191,604 -13,044	-6%	-$408K	0.36%	90
2016 Q4	$6.39M	Sell	204,648 -5,220	-2%	-$169K	0.4%	79
2016 Q3	$8.43M	Sell	209,868 -4,752	-2%	-$179K	0.62%	46
2016 Q2	$7.13M	Sell	214,620 -23,238	-10%	-$795K	0.53%	68
2016 Q1	$6.99M	Sell	237,858 -42,150	-15%	-$1.16M	0.52%	63
2015 Q4	$7.37K	Buy	280,008 +1,644	+0.6%	+$42.7K	0.53%	64
2015 Q3	$6.6K	Buy	278,364 +20,256	+8%	+$489K	0.49%	66
2015 Q2	$5.45K	Hold	258,108	–	–	0.38%	94
2015 Q1	$5.45K	Buy	258,108 +92,526	+56%	+$2.08M	0.38%	94
2014 Q4	$3.52M	Buy	+165,582	New	+$3.33M	0.25%	131

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

First National Bank of Omaha's EW Position: Q1 2026 in Review

First National Bank of Omaha reduced its Edwards Lifesciences (EW) stake by 0.87% in Q1 2026, selling an estimated $27.8K and leaving 38,519 shares worth $3.08M. The position accounts for 0.1% of the portfolio, ranked #211.

First National Bank of Omaha first reported a position in EW in Q4 2014 and has held it in 46 quarters since. The position peaked at $8.74M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

First National Bank of Omaha held 38,519 shares of Edwards Lifesciences worth $3.08M as of Q1 2026.
First National Bank of Omaha sold 337 Edwards Lifesciences shares in Q1 2026, an estimated $27.8K.
Edwards Lifesciences made up 0.1% of First National Bank of Omaha's portfolio in Q1 2026, its #211 holding.
First National Bank of Omaha first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 46 quarters since.
First National Bank of Omaha's Edwards Lifesciences position peaked at $8.74M in Q4 2021.
1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on First National Bank of Omaha's 13F filing for Q1 2026, filed 11 May 2026.